TABLE 1.

Summary of anti-EGFR ADCs in clinical investigation.

ADC	mAb	Payload	Linker	DAR	Conditions	Clinical phase	Company
ABT-414	Anti-EGFR mAb (ABT-806)	MMAF	Non-cleavable mc linker	4	Glioblastoma	II/III	AbbVie
MRG003	Anti-EGFR mAb	MMAE	Cleavable vc linker	n/a	Biliary tract cancer, nasopharyngeal carcinoma, squamous cell carcinoma of head and neck, non-small cell lung cancer	Ⅱ	Miracogen
M1231	Bispecific antibody that targets MUC1 and EGFR	Hemiasterlin	n/a	n/a	Metastatic solid tumors, esophageal cancer, non-small cell lung cancer	I	Sutro, EMD Serono

ADC: antibody-drug conjugates; DAR: drug-to-antibody ratio; mAb: monoclonal antibody; mc: maleimidocaproyl; MMAE: monomethyl auristatin E; MMAF: monomethyl auristatin F; vc: valine-citrulline.